Antimicrobial activity of LY164846, a new oral cephalosporin, and recommendations for disk diffusion tests.
LY164846 is a new oral cephalosporin with a limited spectrum of antimicrobial activity that includes staphylococci (other than methicillin-resistant), streptococci (other than enterococci), Haemophilus influenzae (beta-lactamase-negative and beta-lactamase-positive), Branhamella catarrhalis (beta-lactamase-negative and beta-lactamase-positive), and Neisseria species (beta-lactamase negative and beta-lactamase-positive). The tentative recommendations for susceptibility breakpoints are less than or equal to 4 micrograms/ml and greater than or equal to 19 mm for susceptible, 8 micrograms/ml and 15-18 mm for intermediate, and greater than or equal to 16 micrograms/ml and less than or equal to 14 mm for resistant.
D002511:Cephalosporins / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects; D006190:Haemophilus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D009346:Neisseriaceae / Q000187:drug effects*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects*; D013291:Streptococcus / Q000187:drug effects*
D002511:Cephalosporins; C048386:LY 164846